# Tenet Healthcare Corp: Form 10-Q for the period ended Mar 31, 2017

- Company: [Tenet Healthcare Corp](/companies/thc.md) (CIK 70318)
- Form: 10-Q
- Filed: 2017-05-01
- Accepted by EDGAR: May 1, 2017, 16:39 ET
- Period: 2017-03-31
- Accession: 0001558370-17-003181
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/70318/000155837017003181/thc-20170331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/70318/000155837017003181/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | $267.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-01-01 to 2017-03-31 | $258.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-01-01 to 2017-03-31 | −$33.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | $36.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-01-01 to 2017-03-31 | 100,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2017-01-01 to 2017-03-31 | $186.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2017-01-01 to 2017-03-31 | $198.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-03-31 | $572.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $5.05bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $24.51bn | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $3.77bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $20.99bn | us-gaap:Liabilities |
| Shareholders' equity | at 2017-03-31 | $430.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 103,059 characters.

### INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. Our Hospital Operations and other segment is comprised of our acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals, physician practices and health plans (certain of which are classified as held for sale as described in Note 3 to our Condensed Consolidated Financial Statements). Our Ambulatory Care segment is comprised of the operations of our USPI Holding Company, Inc. (“USPI joint venture”), in which we own a majority interest, and European Surgical Partners Limited (“Aspen”) facilities. At March 31, 2017, our USPI joint venture had interests in 240 ambulatory surgery centers, 34 urgent care centers, 21 imaging centers and 20 short-stay surgical hospitals in 27 states, and Aspen operated nine private hospitals and clinics in the United Kingdom. Our Conifer segment provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities, through our Conifer Holdings, Inc. (“Conifer”) subsidiary. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

- Management Overview
- Forward-Looking Statements
- Sources of Revenue
- Results of Operations
- Liquidity and Capital Resources
- Off-Balance Sheet Arrangements
- Critical Accounting Estimates

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per share, per admission, per adjusted admission, per patient day, per adjusted patient day, per visit and per case amounts). Continuing operations information includes the results of (i) our same 75 hospitals operated throughout the three months ended March 31, 2017 and 2016, (ii) our five Georgia hospitals, which we divested effective April 1, 2016, and (iii) The Hospitals of Providence (“THOP”) Transmountain Campus, a new teaching hospital we opened on January 17, 2017 in El Paso. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes.

### MANAGEMENT OVERVIEW

### RECENT DEVELOPMENTS

*Accelerating the Purchase of Noncontrolling Interests in our USPI Joint Venture—*In April 2017, we amended our previously disclosed Put/Call Agreement, as described and defined in Note 11 to our accompanying Condensed Consolidated Financial Statements, to provide for, among other things, the acceleration of our acquisition of certain shares of our USPI joint venture such that, on or before July 3, 2017, we will own 80% of the outstanding shares of our USPI joint venture. Currently, we own approximately 56.3% of the USPI joint venture. Under the terms of the amendment, we will pay Welsh, Carson, Anderson & Stowe (“Welsh Carson”) approximately $711 million, to buy 23.7% of our USPI joint venture, which amount will be subject to adjustment for actual 2017 results in accordance with the terms of the Put/Call Agreement. Increasing our ownership in the USPI joint venture to 80% will allow us to use our net operating loss carryforwards to offset the federal cash taxes that our USPI joint venture would otherwise pay in 2017 and future years until our carryforwards are fully utilized. The closing of the purchase is expected to occur on or before July 3, 2017. We expect to fund the consideration from general sources of corporate liquidity, including cash on hand, proceeds from asset divestitures and borrowings under our credit agreement.

The amended agreement also provides that the remaining 15.0% ownership interest in our USPI joint venture held by Welsh Carson will be subject to put options in equal shares in each of 2018 and 2019. In the event Welsh Carson does not exercise these put options, we will have the option to buy 7.5% of our USPI joint venture from Welsh Carson in 2018 and another 7.5% in 2019. As a result, we could own 95% of our USPI joint venture as soon as 2019, with the remaining 5% owned by Baylor University Medical Center. In connection with such puts or calls, we will have the ability to choose whether to settle the purchase price in cash or shares of our common stock.

*Divestiture of Health Plan in Arizona and our Home Health and Hospice Businesses—*On May 1, 2017, we sold the membership of our VHS Phoenix Health Plan, Inc., a Medicaid-managed health plan operating as Phoenix Health Plan in Arizona, for proceeds of approximately $13 million. Also on May 1, 2017, we completed the sale of the majority of our home health and hospice businesses for proceeds of approximately $20 million. We do not expect to record impairment charges as a result of these transactions.

*Definitive Agreement to Sell Three Acute Care Hospitals and Related Operations in Houston—*Additionally on May 1, 2017, we announced a definitive agreement to sell three of our acute care hospitals and related operations in Houston, Texas (not including any of our Ambulatory Care facilities). Our portion of the proceeds from the sale will be approximately $725 million. We do not expect to record an impairment charge as a result of this anticipated transaction. This sale, which is subject to customary closing conditions, including regulatory approvals, is expected to be completed by the third quarter of 2017.

### TRENDS AND STRATEGIES

The healthcare industry, in general, and the acute care hospital business, in particular, are experiencing

significant regulatory uncertainty based, in large part, on legislative efforts to significantly modify or repeal and potentially replace the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”). It is difficult to predict the full impact of these actions on our future revenues and operations. However, we believe that our ultimate success in increasing our profitability depends in part on our success in executing the strategies discussed below. In general, these strategies are intended to address the following trends shaping the demand for healthcare services: (i) consumers, employers and insurers are actively seeking lower-cost solutions and better value as they focus more on healthcare spending; (ii) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (iii) the industry is migrating to value-based payment models with government and private payers shifting risk to providers; and (iv) consolidation continues across the entire healthcare sector through both traditional acquisition and divestiture activities, as well as joint ventures.

*Driving Growth in Our Facilities—*Over the past several years, and with the aforementioned trends in mind, we have taken a number of steps to better position our hospitals, ambulatory care centers and other outpatient businesses to compete more effectively in the ever evolving healthcare environment. We have set competitive prices for our services, made capital and other investments in our facilities and technology, increased our efforts to recruit and retain quality physicians, nurses and other healthcare personnel, and negotiated competitive contracts with managed care and other private payers. In addition, we have expanded our network of outpatient centers, and we have increased the participation of our hospitals in accountable care organizations (“ACOs”), which are networks of providers and suppliers that work together to invest in infrastructure and to redesign delivery processes in an effort to achieve high quality and efficient delivery of services. We have also entered into joint ventures with other healthcare providers in several of our markets to maximize effectiveness, reduce costs and build clinically integrated networks that provide quality services across the care continuum.

We believe we are well-positioned to generate returns on recent hospital projects, including our new 106-bed teaching hospital in El Paso, which opened on January 17, 2017. We are also continuing our strategy of selling assets in non-core markets, such as our former hospitals and related operations in Georgia and North Carolina, as well as sub-scale businesses, such as our health plans. We will continue to further refine our portfolio of hospitals and related healthcare businesses when we believe such refinements will help us achieve one or more of the following goals: improve profitability;

allocate capital more effectively in areas where we have a stronger market presence; deploy proceeds on higher-return investments across our business; enhance cash generation; and lower our ratio of debt-to-Adjusted EBITDA.

*Expansion of Our Ambulatory Care Segment—*We remain focused on opportunities to expand our Ambulatory Care segment through organic growth, building new outpatient centers, corporate development activities and strategic partnerships. We believe surgery centers and surgical hospitals like those in our USPI joint venture offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable in a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to steadily increase. In addition, we have continued to grow our imaging and urgent care businesses through our USPI joint venture’s acquisitions. These acquisitions reflect our broader strategies to (1) offer more services to patients, (2) broaden the capabilities we offer to healthcare systems and physicians, and (3) expand into faster-growing, less capital intensive, higher-margin businesses. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

*Driving Conifer’s Growth—*We intend to continue to market and expand Conifer’s revenue cycle management, patient communications and engagement services, and value-based care services businesses. Conifer provides services to more than 800 Tenet and non-Tenet hospital and other clients nationwide. Conifer’s service offerings have also expanded to support value-based performance through clinical integration, financial risk management and population health management, which are integral parts of the healthcare industry’s movement toward ACOs and similar risk-based or capitated contract models. In addition to hospitals and independent physician associations, clients for these services include health plans, self-insured organizations, government agencies and other entities.

*Improving Operating Leverage—*We are focused on improving profitability by growing patient volumes and effective cost management. We believe our patient volumes have been constrained by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co-pays and deductibles, depressed economic conditions in certain of our markets and demographic trends. However, we also believe that targeted capital spending on critical growth opportunities for our hospitals, emphasis on higher-demand clinical service lines (including outpatient services), focus on expanding our outpatient business and the implementation of new payer contracting strategies should help us grow our patient volumes. In addition, we believe our capital structure will withstand a changing interest rate environment. Approximately 94% of our long-term debt has a fixed rate of interest, and the maturity dates of our notes are staggered from 2018 through 2031. Moreover, we intend to lower our ratio of debt-to-Adjusted EBITDA, primarily through Adjusted EBITDA growth, which should lower our refinancing risk and increase the potential for us to use lower-rate secured debt to refinance portions of our higher-rate unsecured debt.

Our ability to execute on our strategies and manage the aforementioned trends is subject to a number of risks and uncertainties that may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”).

### RESULTS OF OPERATIONS—OVERVIEW

The following tables show certain selected operating statistics for our continuing operations, which includes the results of (i) our same 75 hospitals operated throughout the three months ended March 31, 2017 and 2016, (ii) our five Georgia hospitals, which we divested effective April 1, 2016, and (iii) our new THOP Transmountain Campus teaching hospital, which we opened on January 17, 2017 in El Paso. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses.

27

| Selected Operating Statistics Hospital Operations and other | Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 76 | 80 | (4) (1) |
| Total admissions | 196,907 | 211,799 | (7.0)% |
| Adjusted patient admissions(2) | 347,150 | 362,819 | (4.3)% |
| Paying admissions (excludes charity and uninsured) | 186,648 | 201,436 | (7.3)% |
| Charity and uninsured admissions | 10,259 | 10,363 | (1.0)% |
| Emergency department visits | 733,051 | 789,916 | (7.2)% |
| Total surgeries | 121,404 | 132,584 | (8.4)% |
| Patient days — total | 923,339 | 1,010,514 | (8.6)% |
| Adjusted patient days(2) | 1,603,698 | 1,714,369 | (6.5)% |
| Average length of stay (days) | 4.69 | 4.77 | (1.7)% |
| Average licensed beds | 20,440 | 21,524 | (5.0)% |
| Utilization of licensed beds(3) | 50.2% | 51.6% | (1.4) %(1) |
| Total visits | 2,039,942 | 2,146,618 | (5.0)% |
| Paying visits (excludes charity and uninsured) | 1,908,212 | 1,984,515 | (3.8)% |
| Charity and uninsured visits | 131,730 | 162,103 | (18.7)% |
| **Ambulatory Care** |  |  |  |
| Total consolidated facilities (at end of period) | 217 | 211 | 6 (1) |
| Total cases | 455,576 | 444,239 | 2.6% |

(1) The change is the difference between the 2017 and 2016 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions decreased by 14,892, or 7.0%, in the three months ended March 31, 2017 compared to the three months ended March 31, 2016, and total surgeries decreased by 11,180, or 8.4%, in the three months ended March 31, 2017 compared to the 2016 period. In addition, our emergency department visits decreased 7.2% in the three months ended March 31, 2017 compared to the same period in the prior year. Our volumes from continuing operations in the three months ended March 31, 2017 compared to the three months ended March 31, 2016 were negatively impacted by the decrease in our number of hospitals, a leap-year day in the 2016 period, and our out-of-network status with a national payer. Our Ambulatory Care total cases increased 2.6% due to the increase in consolidated facilities.

| Revenues Net operating revenues before provision for doubtful accounts | Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Hospital Operations and other | $4,332 | $4,598 | (5.8)% |
| Ambulatory Care | 462 | 437 | 5.7% |
| Conifer | 402 | 385 | 4.4% |
| Total | 5,196 | 5,420 | (4.1)% |
| Selected Hospital Operations and other revenue data |  |  |  |
| Net inpatient revenues | $2,609 | $2,781 | (6.2)% |
| Net outpatient revenues | $1,482 | $1,514 | (2.1)% |
| Self-pay net inpatient revenues | $106 | $78 | 35.9% |
| Self-pay net outpatient revenues | $151 | $145 | 4.1% |
| Total self-pay revenues | $257 | $223 | 15.2% |

Net operating revenues before provision for doubtful accounts decreased by $224 million, or 4.1%, in the three months ended March 31, 2017 compared to the same period in 2016, primarily due to lower inpatient and outpatient volumes. The 2016 period also included $57 million of net revenues from the California provider fee program, the extension of which has not yet been approved by CMS for the three months ended March 31, 2017. For our Hospital Operations and other segment, the impact of lower volumes on net operating revenues was partially mitigated by improved managed care pricing.

| Provision for Doubtful Accounts Provision for doubtful accounts | Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Hospital Operations and other | $376 | $368 | 2.2% |
| Ambulatory Care | 7 | 8 | (12.5)% |
| Total | $383 | $376 | 1.9% |
| Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts |  |  |  |
| Hospital Operations and other | 8.7% | 8.0% | 0.7 %(1) |
| Ambulatory Care | 1.5% | 1.8% | (0.3) %(1) |
| Total | 7.4% | 6.9% | 0.5 %(1) |

(1) The change is the difference between the 2017 and 2016 amounts shown.

Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts was 7.4% and 6.9% for the three months ended March 31, 2017 and 2016, respectively. This increase was primarily due to increases in uninsured revenues. Our accounts receivable days outstanding (“AR Days”) from continuing operations (which calculation excludes our health plan revenues and California provider fee revenue from the 2016 period because the 2017 program has not yet been approved) were 56.1 days at March 31, 2017 and 56.7 days at December 31, 2016, slightly over our target of less than 55 days.

| Selected Operating Expenses Hospital Operations and other | Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,980 | $2,010 | (1.5)% |
| Supplies | 671 | 725 | (7.4)% |
| Other operating expenses | 1,015 | 1,073 | (5.4)% |
| Total | $3,666 | $3,808 | (3.7)% |
| **Ambulatory Care** |  |  |  |
| Salaries, wages and benefits | $150 | $146 | 2.7% |
| Supplies | 94 | 86 | 9.3% |
| Other operating expenses | 85 | 86 | (1.2)% |
| Total | $329 | $318 | 3.5% |
| **Conifer** |  |  |  |
| Salaries, wages and benefits | $250 | $239 | 4.6% |
| Other operating expenses | 87 | 83 | 4.8% |
| Total | $337 | $322 | 4.7% |
| **Total** |  |  |  |
| Salaries, wages and benefits | $2,380 | $2,395 | (0.6)% |
| Supplies | 765 | 811 | (5.7)% |
| Other operating expenses | 1,187 | 1,242 | (4.4)% |
| Total | $4,332 | $4,448 | (2.6)% |
| Rent/lease expense(1) |  |  |  |
| Hospital Operations and other | $62 | $61 | 1.6% |
| Ambulatory Care | 18 | 17 | 5.9% |
| Conifer | 5 | 4 | 25.0% |
| Total | $85 | $82 | 3.7% |

(1) Included in other operating expenses.

29

| Selected Operating Expenses per Adjusted Patient Admission Hospital Operations and other | Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits per adjusted patient admission(1) | $5,689 | $5,526 | 2.9% |
| Supplies per adjusted patient admission(1) | 1,933 | 1,997 | (3.2)% |
| Other operating expenses per adjusted patient admission(1) | 2,668 | 2,580 | 3.4% |
| Total per adjusted patient admission | $10,290 | $10,103 | 1.9% |

(1) Calculation excludes the expenses from our health plan businesses. Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits per adjusted patient admission increased 2.9% in the three months ended March 31, 2017 compared to the same period in 2016. This change is primarily due to annual merit increases for certain of our employees, increased health benefits costs and the effect of lower volumes on operating leverage due to certain fixed staffing costs.

Supplies expense per adjusted patient admission decreased 3.2% in the three months ended March 31, 2017 compared to the three months ended March 31, 2016. The change in supplies expense was primarily attributable to lower volumes in our higher acuity supply-intensive surgical services and the benefit of the group-purchasing strategies and supplies-management services we utilize to reduce costs.

Other operating expenses per adjusted patient admission increased by 3.4% in the three months ended March 31, 2017 compared to the prior-year period. This increase is due to higher contracted services and medical fees, as well as the effect of lower volumes on operating leverage due to certain fixed costs. Malpractice expense for our Hospital Operations and other segment was $23 million lower in the 2017 period compared to the 2016 period. There was minimal impact in the 2017 period from the three basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2016 period, we recognized an unfavorable adjustment of approximately $12 million as a result of a 55 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities.

### LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $572 million at March 31, 2017 compared to $716 million at December 31, 2016.

Significant cash flow items in the three months ended March 31, 2017 included:

- Capital expenditures of $198 million; and
- Interest payments of $130 million.

Net cash provided by operating activities was $186 million in the three months ended March 31, 2017 compared to $147 million in the three months ended March 31, 2016. Key factors contributing to the change between the 2017 and 2016 periods include the following:

- A $45 million decrease in payments on reserves for restructuring charges, acquisition-related costs, and litigation costs and settlements; and
- A $6 million decrease in cash used in discontinued operations.

### FORWARD-LOOKING STATEMENTS

This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements. These forward-looking statements represent management’s current expectations, based on currently available information, as to the outcome and timing of future events. They involve known and unknown risks, uncertainties and other factors — many of which we are unable to predict or control — that may cause our actual results, performance or achievements, or healthcare industry results, to be materially different from those expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risks described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

When considering forward-looking statements, a reader should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in our Annual Report or this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statement. We specifically disclaim any obligation to update any information contained in a forward-looking statement or any forward-looking statement in its entirety and, therefore, disclaim any resulting liability for potentially related damages.

All forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

### HOSPITAL OPERATIONS AND OTHER SEGMENT SOURCES OF REVENUE

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-based health insurance companies and self-pay patients (that is, patients who do not have health insurance and are not covered by some other form of third-party arrangement).

The table below shows the sources of net patient revenues before provision for doubtful accounts for our Hospital Operations and other segment, expressed as percentages of net patient revenues before provision for doubtful accounts from all sources:

| Net Patient Revenues from: | Three Months Ended March 31, 2017 | 2016 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Medicare | 21.0% | 20.0% | 1.0% |
| Medicaid | 6.7% | 8.7% | (2.0)% |
| Managed care | 62.3% | 61.1% | 1.2% |
| Indemnity, self-pay and other | 10.0% | 10.2% | (0.2)% |

(1) The increase (decrease) is the difference between the 2017 and 2016 percentages shown.

Our payer mix on an admissions basis for our Hospital Operations and other segment, expressed as a percentage of total admissions from all sources, is shown below:

| Admissions from: | Three Months Ended March 31, 2017 | 2016 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Medicare | 27.0% | 27.2% | (0.2)% |
| Medicaid | 6.4% | 7.3% | (0.9)% |
| Managed care | 59.0% | 58.1% | 0.9% |
| Indemnity, self-pay and other | 7.6% | 7.4% | 0.2% |

(1) The increase (decrease) is the difference between the 2017 and 2016 percentages shown.

### GOVERNMENT PROGRAMS

The Centers for Medicare and Medicaid Services (“CMS”), an agency of the U.S. Department of Health and Human Services (“HHS”), is the single largest payer of healthcare services in the United States. Approximately 55 million individuals rely on healthcare benefits through Medicare, and approximately 74 million individuals are enrolled in Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and directed by CMS. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, certain younger people with disabilities, and people with end-stage renal disease, and is provided without regard to income or assets. Medicaid is administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The CHIP, which is also administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and periodically requires the enactment of reauthorizing legislation. The current authorizing legislation will expire on September 30, 2017, and we cannot predict what action the federal government may take with regard to the continuation of the CHIP.

### Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee-for-service payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private fee-for-service Medicare special needs plans and Medicare medical savings account plans. The major components of our net patient revenues from continuing operations of our Hospital Operations and other segment for services provided to patients enrolled in the Original Medicare Plan for the three months ended March 31, 2017 and 2016 are set forth in the following table:

| Revenue Descriptions | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Medicare severity-adjusted diagnosis-related group — operating | $450 | $474 |
| Medicare severity-adjusted diagnosis-related group — capital | 41 | 43 |
| Outliers | 21 | 22 |
| Outpatient | 241 | 222 |
| Disproportionate share | 71 | 78 |
| Direct Graduate and Indirect Medical Education(1) | 66 | 64 |
| Other(2) | — | (17) |
| Adjustments for prior-year cost reports and related valuation allowances | 12 | 13 |
| **Total Medicare net patient revenues** | **$902** | **$899** |

(1) Includes Indirect Medical Education revenues earned by our children’s hospitals under the Children’s Hospitals Graduate Medical Education Payment Program administered by the Health Resources and Services Administration of HHS.

(2) The other revenue category includes inpatient psychiatric units, inpatient rehabilitation units, one long-term acute care hospital, other revenue adjustments, and adjustments related to the estimates for current-year cost reports and related valuation allowances.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

### Medicaid

Medicaid programs and the corresponding reimbursement methodologies are administered by the states and vary from state to state and from year to year. Estimated revenues under various state Medicaid programs, including state-funded managed care Medicaid programs, constituted approximately 17.6% and 19.0% of total net patient revenues before provision for doubtful accounts of our continuing general hospitals for the three months ended March 31, 2017 and 2016, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. For the three months ended March 31, 2017 and 2016, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $158 million and $227 million, respectively. Our total Medicaid revenues for the 2016 period also included $57 million from the California provider fee program, the extension of which has not yet been approved by CMS for the three months ended March 31, 2017.

Several states in which we operate face budgetary challenges that have resulted, and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted provider fee programs or received waivers under Section 1115 of the Social Security Act. Under a Medicaid waiver, the federal government waives certain Medicaid requirements, thereby giving states flexibility in the operation of their Medicaid program to allow states to test new approaches and demonstration projects to improve care. Generally the Section 1115 waivers are for a period of five years with an option to extend the waiver for three additional years. Continuing pressure on state budgets and other factors could result in future reductions to Medicaid payments, payment delays or additional taxes on hospitals.

Because we cannot predict what actions the federal government or the states may take under existing legislation and future legislation to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation might have on our business, but the impact on our future financial position, results of operations or cash flows could be material.

Medicaid-related patient revenues from continuing operations recognized by our Hospital Operations and other segment from Medicaid-related programs in the states in which our hospitals are located, as well as from Medicaid programs in neighboring states, for the three months ended March 31, 2017 and 2016 are set forth in the table below:

| Hospital Location | Three Months Ended March 31, 2017 Medicaid | Managed Medicaid | 2016 Medicaid | Managed Medicaid |
| --- | ---: | ---: | ---: | ---: |
| Michigan | $93 | $87 | $98 | $73 |
| Texas | 48 | 60 | 52 | 61 |
| California | 42 | 109 | 104 | 103 |
| Alabama | 22 | — | 27 | — |
| Florida | 19 | 42 | 22 | 42 |
| Illinois | 19 | 17 | 18 | 18 |
| Pennsylvania | 19 | 50 | 19 | 51 |
| Massachusetts | 8 | 12 | 8 | 14 |
| South Carolina | 3 | 9 | 2 | 9 |
| Arizona | 1 | 50 | 4 | 55 |
| Missouri | 1 | — | (1) | — |
| Georgia | — | — | 19 | 9 |
| Tennessee | — | 8 | 1 | 8 |
|  | **$275** | **$444** | **$373** | **$443** |

33

### Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems are provided below.

#### Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems

Under Medicare law, CMS is required to annually update certain rules governing the inpatient prospective payment systems (“IPPS”). The updates generally become effective October 1, the beginning of the federal fiscal year (“FFY”). On April 14, 2017, CMS issued Proposed Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2018 Rates (“Proposed IPPS Rule”). The Proposed IPPS Rule includes the following payment and policy changes:

- A market basket increase of 2.9% for Medicare severity-adjusted diagnosis-related group (“MS-DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record (“EHR”) technology (hospitals that do not report specified quality measure data and/or are not meaningful users of EHR technology will receive a reduced market basket increase); CMS is also proposing certain adjustments to the estimated 2.9% market basket increase that result in a net operating payment update of 1.6% (before budget neutrality adjustments), including:
- Market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.4%, respectively;
- A 0.4588% increase required under the 21st Century Cures Act; and
- A reduction of 0.6% to reverse the one-time increase of 0.6% made in FFY 2017 to address the effects of the 0.2% reduction in effect for FFYs 2014 through 2016 related to the two-midnight rule.
- Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share (“UC-DSH”) payments, including a proposal to transition from using low-income days to estimated uncompensated care costs for the distribution of the UC-DSH pool;
- A 1.03% net increase in the capital federal MS-DRG rate; and
- An increase in the cost outlier threshold from $23,573 to $26,713.

According to CMS, the combined impact of the payment and policy changes in the Proposed IPPS Rule for operating costs will yield an average 1.7% increase in operating MS-DRG payments for hospitals in large urban areas (populations over one million) in FFY 2018. All of the proposed payment and policy changes affecting operating MS-DRG payments and other proposals, notably those affecting Medicare UC-DSH payments, result in an estimated 1.1% increase in our annual fee-for-service IPPS payments, or approximately $24 million. The Proposed IPPS Rule is subject to a comment period that expires on June 13, 2017; we expect the final IPPS rule to be issued on or before August 2, 2017. Because of the uncertainty regarding factors that may influence our future IPPS payments by individual hospital, including legislative action, admission volumes, length of stay and case mix, as well as potential changes to the proposed rule, we cannot provide any assurances regarding our estimate of the impact of the proposed changes.

### PRIVATE INSURANCE

### Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full-service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost-effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non-contracted healthcare providers for non-emergency care.

PPOs generally offer limited benefits to members who use non-contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co-pays, co-insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high-deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient revenues during both the three months ended March 31, 2017 and 2016 was $2.6 billion. Approximately 61% of our managed care net patient revenues for the three months ended March 31, 2017 was derived from our top ten managed care payers. National payers generated approximately 47% of our total net managed care revenues. The remainder comes from regional or local payers. At March 31, 2017 and December 31, 2016, approximately 64% and 66%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from managed care payers.

In April 2017, we successfully concluded negotiations with a national payer to return to their provider network after ceasing our participation on October 1, 2016. As a result of this new agreement, our hospitals and other healthcare facilities, as well as our employed physicians, will be added to the payer’s national provider network on either June 1, 2017 or October 1, 2017. Prior to expiration of the contract on October 1, 2016, the contract represented approximately 2.9% of our net operating revenues before provision for doubtful accounts for the period subsequent to the sale of our Georgia hospitals on March 31, 2016 to the contract expiration on September 30, 2016.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at March 31, 2017, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $15 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-house and discharged-not-final-billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our operating income. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefitted from solid year-over-year aggregate managed care pricing improvements for several years, we have seen these improvements moderate recently, and we believe the moderation could continue in future years. In the three months ended March 31, 2017, our commercial managed care net inpatient revenue per admission from our acute care hospitals was approximately 86% higher than our aggregate yield on a per admission basis from government payers, including managed Medicare and Medicaid insurance plans.

### Indemnity

An indemnity-based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

### SELF-PAY PATIENTS

Self-pay patients are patients who do not qualify for government programs, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our self-pay patients are admitted through our hospitals’ emergency departments and often require high-acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self-pay accounts pose significant collectability problems. At both March 31, 2017 and December 31, 2016, approximately 4% of our net accounts receivable for our Hospital Operations and other segment were due from self-pay patients. Further, a significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co‑pays and deductibles owed to us by patients with insurance. We provide revenue cycle management services through our Conifer subsidiary, which is subject to various laws, rules and regulations regarding consumer finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, in Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our provision for doubtful accounts in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non-emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co-pay and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical-based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address this challenge. For example, our *Compact with Uninsured Patients (“*Compact”) is designed to offer managed care-style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. A significant portion of those charges had previously been written down in our provision for doubtful accounts. Under the Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for self-pay accounts and other factors that affect the estimation process.

We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. Generally, our method of measuring the estimated costs uses adjusted self-pay/charity patient days multiplied by selected operating expenses (which include salaries, wages and benefits, supplies and other operating expenses) per adjusted patient day. The adjusted self‑pay/charity patient days represents actual self-pay/charity patient days adjusted to include self-pay/charity outpatient services by multiplying actual self-pay/charity patient days by the sum of gross self-pay/charity inpatient revenues and gross self-pay/charity outpatient revenues and dividing the results by gross self-pay/charity inpatient revenues. The following table shows our estimated costs (based on selected operating expenses) of caring for self-pay patients and charity care patients, as well as revenues attributable to Medicaid DSH and other supplemental revenues we recognized, in the three months ended March 31, 2017 and 2016:

| Estimated costs for: | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Self-pay patients | $160 | $165 |
| Charity care patients | $30 | $44 |
| Medicaid DSH and other supplemental revenues | $158 | $227 |

The expansion of health insurance coverage has resulted in an increase in the number of patients using our facilities who have either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of states to expand Medicaid coverage and for persons living in the country illegally who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.

### RESULTS OF OPERATIONS

The following two tables summarize our consolidated net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, for the three months ended March 31, 2017 and 2016:

| Net operating revenues: | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| General hospitals | $4,095 | $4,302 |
| Other operations | 1,101 | 1,118 |
| Net operating revenues before provision for doubtful accounts | 5,196 | 5,420 |
| Less provision for doubtful accounts | 383 | 376 |
| **Net operating revenues** | **4,813** | **5,044** |
| **Equity in earnings of unconsolidated affiliates** | **29** | **24** |
| Operating expenses: |  |  |
| Salaries, wages and benefits | 2,380 | 2,395 |
| Supplies | 765 | 811 |
| Other operating expenses, net | 1,187 | 1,242 |
| Electronic health record incentives | (1) | — |
| Depreciation and amortization | 221 | 212 |
| Impairment and restructuring charges, and acquisition-related costs | 33 | 28 |
| Litigation and investigation costs | 5 | 173 |
| Gains on sales, consolidation and deconsolidation of facilities | (15) | (147) |
| **Operating income** | **$267** | **$354** |

37

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Net operating revenues | 100.0% | 100.0% |
| Equity in earnings of unconsolidated affiliates | 0.6% | 0.5% |
| Operating expenses: |  |  |
| Salaries, wages and benefits | 49.4% | 47.5% |
| Supplies | 15.9% | 16.1% |
| Other operating expenses, net | 24.7% | 24.6% |
| Depreciation and amortization | 4.6% | 4.2% |
| Impairment and restructuring charges, and acquisition-related costs | 0.7% | 0.6% |
| Litigation and investigation costs | 0.1% | 3.4% |
| Gains on sales, consolidation and deconsolidation of facilities | (0.3)% | (2.9)% |
| **Operating income** | **5.5%** | **7.0%** |

Net operating revenues of our general hospitals include inpatient and outpatient revenues for services provided by facilities in our Hospital Operations and other segment, as well as nonpatient revenues (e.g., rental income, management fee revenue, and income from services such as cafeterias, gift shops and parking) and other miscellaneous revenue. Net operating revenues of other operations primarily consist of revenues from (1) physician practices, (2) a long-term acute care hospital, (3) our Ambulatory Care segment, (4) services provided by our Conifer subsidiary to third parties and (5) our health plans. Revenues from our general hospitals represented approximately 79% of our total net operating revenues before provision for doubtful accounts for both the three months ended March 31, 2017 and 2016.

Net operating revenues from our other operations were $1.101 billion and $1.118 billion in the three months ended March 31, 2017 and 2016. The decrease in net operating revenues from other operations during 2017 primarily relates to our health plans, partially offset by increases in revenue cycle services provided by our Conifer subsidiary and revenues from our USPI joint venture. Equity earnings of unconsolidated affiliates were $29 million and $24 million for the three months ended March 31, 2017 and 2016, respectively. The increase in equity earnings of unconsolidated affiliates in the 2017 period compared to the 2016 period primarily related to our USPI joint venture.

The following table shows selected operating expenses of our three reportable business segments. Information for our Hospital Operations and other segment is presented on a same-hospital basis, which includes the results of our same 75 hospitals operated throughout the three months ended March 31, 2017 and 2016. The results of our five Georgia hospitals, which we divested effective April 1, 2016, and our new THOP Transmountain Campus teaching hospital, which we opened on January 17, 2017 in El Paso, are excluded from our same-hospital information.

38

| Selected Operating Expenses Hospital Operations and other — Same-Hospital | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,967 | $1,928 | 2.0% |
| Supplies | 668 | 702 | (4.8)% |
| Other operating expenses | 1,000 | 1,020 | (2.0)% |
| Total | $3,635 | $3,650 | (0.4)% |
| **Ambulatory Care** |  |  |  |
| Salaries, wages and benefits | $150 | $146 | 2.7% |
| Supplies | 94 | 86 | 9.3% |
| Other operating expenses | 85 | 86 | (1.2)% |
| Total | $329 | $318 | 3.5% |
| **Conifer** |  |  |  |
| Salaries, wages and benefits | $250 | $239 | 4.6% |
| Other operating expenses | 87 | 83 | 4.8% |
| Total | $337 | $322 | 4.7% |
| Rent/lease expense(1) |  |  |  |
| Hospital Operations and other | $60 | $59 | 1.7% |
| Ambulatory Care | 18 | 17 | 5.9% |
| Conifer | 5 | 4 | 25.0% |
| Total | $83 | $80 | 3.8% |

(1) Included in other operating expenses.

### RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

- Hospital Operations and other, which is comprised of our acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals, physician practices and health plans (certain of which are classified as held for sale as described in Note 3 to our Condensed Consolidated Financial Statements);
- Ambulatory Care, which is comprised of our USPI joint venture’s ambulatory surgery centers, urgent care centers, imaging centers and short-stay surgical hospitals, as well as Aspen’s hospitals and clinics; and
- Conifer, which provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems and other entities.

### Hospital Operations and other Segment

The following tables show operating statistics of our continuing operations hospitals on a same-hospital basis, which includes the results of our same 75 hospitals operated throughout the three months ended March 31, 2017 and 2016. The results of our five Georgia hospitals, which we divested effective April 1, 2016, and our new THOP Transmountain Campus teaching hospital, which we opened on January 17, 2017 in El Paso, are excluded from our same-hospital information.

39

| Admissions, Patient Days and Surgeries | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 75 | 75 | — (1) |
| Total admissions | 196,182 | 202,873 | (3.3)% |
| Adjusted patient admissions(2) | 339,522 | 348,221 | (2.5)% |
| Paying admissions (excludes charity and uninsured) | 186,079 | 193,286 | (3.7)% |
| Charity and uninsured admissions | 10,103 | 9,587 | 5.4% |
| Admissions through emergency department | 126,067 | 129,606 | (2.7)% |
| Paying admissions as a percentage of total admissions | 94.9% | 95.3% | (0.4) %(1) |
| Charity and uninsured admissions as a percentage of total admissions | 5.1% | 4.7% | 0.4 %(1) |
| Emergency department admissions as a percentage of total admissions | 64.3% | 63.9% | 0.4 %(1) |
| Surgeries — inpatient | 51,723 | 53,739 | (3.8)% |
| Surgeries — outpatient | 69,553 | 74,360 | (6.5)% |
| Total surgeries | 121,276 | 128,099 | (5.3)% |
| Patient days — total | 921,014 | 960,998 | (4.2)% |
| Adjusted patient days(2) | 1,583,962 | 1,637,408 | (3.3)% |
| Average length of stay (days) | 4.69 | 4.74 | (1.1)% |
| Licensed beds (at end of period) | 20,333 | 20,380 | (0.2)% |
| Average licensed beds | 20,334 | 20,375 | (0.2)% |
| Utilization of licensed beds(3) | 50.3% | 52.4% | (2.1) %(1) |

(1) The change is the difference between 2017 and 2016 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

| Outpatient Visits | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Total visits | 2,009,408 | 2,052,169 | (2.1)% |
| Paying visits (excludes charity and uninsured) | 1,883,235 | 1,907,998 | (1.3)% |
| Charity and uninsured visits | 126,173 | 144,171 | (12.5)% |
| Emergency department visits | 703,035 | 733,756 | (4.2)% |
| Surgery visits | 69,553 | 74,360 | (6.5)% |
| Paying visits as a percentage of total visits | 93.7% | 93.0% | 0.7 %(1) |
| Charity and uninsured visits as a percentage of total visits | 6.3% | 7.0% | (0.7) %(1) |

(1) The change is the difference between 2017 and 2016 amounts shown.

| Revenues | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Net operating revenues | $3,937 | $4,060 | (3.0)% |
| Net inpatient revenues | $2,605 | $2,663 | (2.2)% |
| Net outpatient revenues | $1,463 | $1,445 | 1.2% |
| Self-pay net inpatient revenues | $106 | $73 | 45.2% |
| Self-pay net outpatient revenues | 150 | 136 | 10.3% |
| Total self-pay revenues | $256 | $209 | 22.5% |

40

| Revenues on a Per Admission, Per Patient Day and Per Visit Basis | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Net inpatient revenue per admission | $13,278 | $13,126 | 1.2% |
| Net inpatient revenue per patient day | $2,828 | $2,771 | 2.1% |
| Net outpatient revenue per visit | $728 | $704 | 3.4% |
| Net patient revenue per adjusted patient admission(1) | $11,982 | $11,797 | 1.6% |
| Net patient revenue per adjusted patient day(1) | $2,568 | $2,509 | 2.4% |

(1) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

| Provision for Doubtful Accounts | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Provision for doubtful accounts | $372 | $338 | 10.1% |
| Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts | 8.6% | 7.7% | 0.9 %(1) |

(1) The change is the difference between 2017 and 2016 amounts shown.

| Selected Operating Expenses Hospital Operations and other | Same-Hospital Continuing Operations Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | --- |
| Salaries, wages and benefits as a percentage of net operating revenues | 50.0% | 47.5% | 2.5 | %(1) |
| Supplies as a percentage of net operating revenues | 17.0% | 17.3% | (0.3) | %(1) |
| Other operating expenses as a percentage of net operating revenues | 25.4% | 25.1% | 0.3 | %(1) |

(1) The change is the difference between 2017 and 2016 amounts shown.

#### Revenues

Same-hospital net operating revenues decreased $123 million, or 3.0%, during the three months ended March 31, 2017 compared to the three months ended March 31, 2016, primarily due to lower inpatient and outpatient volumes. Our 2017 same-hospital inpatient and outpatient volumes were negatively impacted compared to the 2016 period by a leap-year day in the 2016 period and our out-of-network status with a national payer. The 2016 period also included $57 million of net revenues from the California provider fee program, the extension of which has not yet been approved by CMS for the three months ended March 31, 2017. Same-hospital net inpatient revenues decreased $58 million, or 2.2%, and same-hospital admissions decreased 3.3% in the three months ended March 31, 2017 compared to the same period in 2016. Same-hospital net inpatient revenue per admission increased 1.2%, primarily due to the improved terms of our managed care contracts in the three months ended March 31, 2017 compared to the three months ended March 31, 2016. Same-hospital net outpatient revenues increased $18 million, or 1.2%, while same-hospital outpatient visits decreased 2.1% in the three months ended March 31, 2017 compared to the same period in 2016. Growth in outpatient revenues was primarily driven by improved terms of our managed care contracts. Same-hospital net outpatient revenue per visit increased 3.4% in the three months ended March 31, 2017 compared to the three months ended March 31, 2016, primarily due to the improved terms of our managed care contracts.

#### Provision for Doubtful Accounts

Same-hospital provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts was 8.6% and 7.7% for the three months ended March 31, 2017 and 2016, respectively. The increase in the 2017 period compared to the 2016 period was primarily driven by a $47 million increase in uninsured revenues.

The table below shows the consolidated net accounts receivable and allowance for doubtful accounts by payer at March 31, 2017 and December 31, 2016:

|  | March 31, 2017 Accounts Receivable Before Allowance for Doubtful Accounts | Allowance for Doubtful Accounts | Net | December 31, 2016 Accounts Receivable Before Allowance for Doubtful Accounts | Allowance for Doubtful Accounts | Net |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Medicare | $400 | $— | $400 | $404 | $— | $404 |
| Medicaid | 69 | — | 69 | 46 | — | 46 |
| Net cost report settlements payable and valuation allowances | (15) | — | (15) | (14) | — | (14) |
| Managed care | 1,974 | 183 | 1,791 | 1,965 | 175 | 1,790 |
| Self-pay uninsured | 468 | 423 | 45 | 488 | 442 | 46 |
| Self-pay balance after insurance | 232 | 170 | 62 | 211 | 155 | 56 |
| Estimated future recoveries | 141 | — | 141 | 141 | — | 141 |
| Other payers | 518 | 222 | 296 | 458 | 216 | 242 |
| Total Hospital Operations and other | 3,787 | 998 | 2,789 | 3,699 | 988 | 2,711 |
| Ambulatory Care | 212 | 43 | 169 | 227 | 43 | 184 |
| Total discontinued operations | 2 | — | 2 | 2 | — | 2 |
|  | **$4,001** | **$1,041** | **$2,960** | **$3,928** | **$1,031** | **$2,897** |

A significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. Collection of accounts receivable has been a key area of focus, particularly over the past several years. At March 31, 2017, our Hospital Operations and other segment collection rate on self-pay accounts was approximately 25.8%. Our self-pay collection rate includes payments made by patients, including co-pays and deductibles paid by patients with insurance. Based on our accounts receivable from self-pay patients and co-pays and deductibles owed to us by patients with insurance at March 31, 2017, a 10% decrease or increase in our self-pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to provision for doubtful accounts of approximately $10 million.

Payment pressure from managed care payers also affects our provision for doubtful accounts. We typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations and other segment collection rate from managed care payers was approximately 97.6% at March 31, 2017.

We manage our provision for doubtful accounts using hospital-specific goals and benchmarks such as (1) total cash collections, (2) point-of-service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations and other segment of $2.804 billion and $2.725 billion at March 31, 2017 and December 31, 2016, respectively, excluding cost report settlements payable and valuation allowances of $15 million and $14 million, respectively at March 31, 2017 and December 31, 2016:

42

|  | March 31, 2017 Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| 0-60 days | 92% | 68% | 60% | 26% | 60% |
| 61-120 days | 4% | 17% | 16% | 15% | 13% |
| 121-180 days | 2% | 7% | 9% | 9% | 7% |
| Over 180 days | 2% | 8% | 15% | 50% | 20% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |

|  | December 31, 2016 Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| 0-60 days | 92% | 75% | 61% | 24% | 60% |
| 61-120 days | 5% | 15% | 15% | 14% | 13% |
| 121-180 days | 2% | 4% | 8% | 10% | 6% |
| Over 180 days | 1% | 6% | 16% | 52% | 21% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |

At March 31, 2017, we had a cumulative total of patient account assignments to our Conifer subsidiary of approximately $3.0 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables or in the allowance for doubtful accounts; however, an estimate of future recoveries from all the accounts assigned to our Conifer subsidiary is determined based on our historical experience and recorded in accounts receivable.

Patient advocates from Conifer’s Medicaid Eligibility Program (“MEP”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the MEP, with appropriate contractual allowances recorded. Based on recent trends, approximately 95% of all accounts in the MEP are ultimately approved for benefits under a government program, such as Medicaid. The following table shows the approximate amount of accounts receivable in the MEP still awaiting determination of eligibility under a government program at March 31, 2017 and December 31, 2016 by aging category for the hospitals currently in the program:

|  | March 31, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| 0-60 days | $69 | $84 |
| 61-120 days | 16 | 13 |
| 121-180 days | 3 | 4 |
| Over 180 days | 4 | 4 |
| **Total** | **$92** | **$105** |

#### Salaries, Wages and Benefits

Same-hospital salaries, wages and benefits as a percentage of net operating revenues increased 250 basis points to 50.0% in the three months ended March 31, 2017 compared to the same period in 2016. Same-hospital net operating revenues decreased 3.0% during the three months ended March 31, 2017 compared to the three months ended March 31, 2016, and same-hospital salaries, wages and benefits increased 2.0% in the three months ended March 31, 2017 compared to the 2016 period. The increase in same-hospital salaries, wages and benefits was primarily due to annual merit increases for certain of our employees, increased health benefits costs and the effect of lower volumes on operating leverage due to certain fixed staffing costs. Salaries, wages and benefits expense for the three months ended March 31, 2017 and 2016 included stock-based compensation expense of $9 million and $13 million, respectively.

At March 31, 2017, approximately 23% of the employees in our Hospital Operations and other segment were represented by labor unions. There were no unionized employees in our Ambulatory Care segment, and less than 1% of Conifer’s employees belong to a union. Unionized employees – primarily registered nurses and service and maintenance workers – are located at 34 of our hospitals, the majority of which are in California, Florida and Michigan. We currently have two expired contracts covering approximately 1.2% of our unionized employees and are negotiating renewals under extension agreements. We are also negotiating first contracts at three hospitals and one physician practice covering approximately 5.5% of our unionized employees where employees recently selected union representation. At this time, we are unable to predict the outcome of the negotiations, but increases in salaries, wages and benefits could result from these agreements. Furthermore, there is a possibility that strikes could occur during the negotiation process, which could increase our labor costs and have an adverse effect on our patient admissions and net operating revenues. Organizing activities by labor unions could increase our level of union representation in future periods.

#### Supplies

Same-hospital supplies expense as a percentage of net operating revenues decreased 30 basis points to 17.0% for the three months ended March 31, 2017 compared to the three months ended March 31, 2016. The change in supplies expense was primarily attributable to lower volumes in our higher acuity supply-intensive surgical services and the benefit of the group-purchasing strategies and supplies-management services we utilize to reduce costs.

We strive to control supplies expense through product standardization, contract compliance, improved utilization, bulk purchases and operational improvements. The items of current cost reduction focus continue to be cardiac stents and pacemakers, orthopedics and implants, and high-cost pharmaceuticals.

#### Other Operating Expenses, Net

Same-hospital other operating expenses as a percentage of net operating revenues increased 30 basis points to 25.4% in the three months ended March 31, 2017 compared to the same period in 2016. While same-hospital other operating expenses decreased by $20 million, or 2.0%, net operating revenues decreased by $123 million, or 3.0%. The changes in other operating expenses included:

- increased medical fees of $9 million;
- increased costs of contracted services of $21 million; and
- the effect of lower volumes on operating leverage due to certain fixed costs, partially offset by
- decreased malpractice expense of $20 million; and
- decreased expenses associated with our health plan businesses of $43 million.

There was minimal impact in the 2017 period from the three basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2016 period, we recognized an unfavorable adjustment of approximately $12 million as a result of a 55 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities.

### Ambulatory Care Segment

Our Ambulatory Care segment is comprised of our USPI joint venture’s ambulatory surgery centers, urgent care centers, imaging centers and short-stay surgical hospitals, as well as Aspen’s hospitals and clinics. Our USPI joint venture operates its surgical facilities in partnership with local physicians and, in many of these facilities, a health system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. The joint venture operates facilities on a day-to-day basis through management services contracts. Our sources of earnings from each facility consist of:

- management services revenues, computed as a percentage of each facility’s net revenues (often net of bad debt expense); and
- our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by our USPI joint venture.

Our role as an owner and day-to-day manager provides us with significant influence over the operations of each facility. In many of the facilities our Ambulatory Care segment operates (107 of 324 facilities at March 31, 2017), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. Our USPI joint venture controls 217 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than our USPI joint venture is classified within “net income attributable to noncontrolling interests.”

For unconsolidated affiliates, our consolidated statements of operations reflect our earnings in two line items:

- *equity in earnings of unconsolidated affiliates—*our share of the net income of each facility, which is based on the facility’s net income and the percentage of the facility’s outstanding equity interests owned by us; and
- *management and administrative services revenues, which is included in our net operating revenues—*income we earn in exchange for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less bad debt expense.

Our Ambulatory Care segment operating income is driven by the performance of all facilities our USPI joint venture operates and by the joint venture’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 67% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses.

#### Results of Operations

The following table summarizes certain consolidated statements of operations items for the periods indicated:

| Ambulatory Care Results of Operations | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Net operating revenues | $455 | $429 |
| Equity in earnings of unconsolidated affiliates | $27 | $25 |
| Salaries, wages and benefits | $150 | $146 |
| Supplies | $94 | $86 |
| Other operating expenses, net | $85 | $86 |

Our Ambulatory Care net operating revenues increased by $26 million, or 6.1%, for the three months ended March 31, 2017 compared to the three months ended March 31, 2016. The growth in revenues was primarily driven by increases from acquisitions of $25 million.

Salaries, wages and benefits expense increased by $4 million, or 2.7%, for the three months ended March 31, 2017 compared to the three months ended March 31, 2016. The increase was primarily driven by salaries, wages and benefits expense from acquisitions of $6 million.

Supplies expense increased by $8 million, or 9.3%, for the three months ended March 31, 2017 compared to the three months ended March 31, 2016. The increase was primarily driven by supplies expense from acquisitions of $6 million.

Other operating expenses decreased by $1 million, or 1.2%, for the three months ended March 31, 2017 compared to three months ended March 31, 2016. The increases in other operating expenses related to acquisitions of $4 million were offset by decreases in same-facility other operating expenses of $5 million.

#### Facility Growth

The following table summarizes the changes in our same-facility revenue year-over-year on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.

| Ambulatory Care Facility Growth | Three Months Ended March 31, 2017 |
| --- | ---: |
| Net revenues | 6.1% |
| Cases | 0.5% |
| Net revenue per case | 5.6% |

#### Joint Ventures with Healthcare System Partners

Our USPI joint venture’s business model is to jointly own its facilities with local physicians and not-for-profit healthcare systems. Accordingly, as of March 31, 2017, the majority of facilities in our Ambulatory Care segment are operated in this model.

| Ambulatory Care Facilities with Healthcare System Partners Facilities: | Three Months Ended March 31, 2017 |
| --- | ---: |
| With a healthcare system partner | 179 |
| Without a healthcare system partner | 145 |
| Total facilities operated | 324 |
| Change from December 31, 2016 |  |
| Acquisitions | 2 |
| De novo | — |
| Dispositions/Mergers | (1) |
| Total increase in number of facilities operated | 1 |

### Conifer Segment

Our Conifer segment generated net operating revenues of $402 million and $385 million during the three months ended March 31, 2017 and 2016, respectively, a portion of which was eliminated in consolidation as described in Note 16 to the Condensed Consolidated Financial Statements. The increase in the revenue from third-party customers, which is not eliminated in consolidation, is primarily due to new clients.

Salaries, wages and benefits expense for Conifer increased $11 million, or 4.6%, in the three months ended March 31, 2017 compared to the three months ended March 31, 2016 due to an increase in employee headcount as a result of the growth in Conifer’s business primarily attributable to new clients.

Other operating expenses for Conifer increased $4 million, or 4.8%, in the three months ended March 31, 2017 compared to the three months ended March 31, 2016 due to the growth in Conifer’s business primarily attributable to new clients. Conifer typically incurs start-up and other transition costs during the initial term of new client contracts.

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre-registration, registration, verification of eligibility and benefits, liability identification and collection at point-of-service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

### Consolidated

#### Impairment and Restructuring Charges, and Acquisition-Related Costs

During the three months ended March 31, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $33 million primarily related to our Hospital Operations and other segment, consisting of approximately $1 million to write-down other intangible assets, $16 million of employee severance costs, $2 million of other restructuring costs, $6 million of contract and lease termination fees, and $8 million in acquisition-related costs, which include $2 million of transaction costs and $6 million of acquisition integration charges.

During the three months ended March 31, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $28 million primarily related to our Hospital Operations and other segment, consisting of approximately $2 million to write-down other intangible assets, $10 million of employee severance costs, $1 million of restructuring costs, $1 million of contract and lease termination fees, and $14 million in acquisition-related costs, which include $5 million of transaction costs and $9 million of acquisition integration charges.

#### Litigation and Investigation Costs

Litigation and investigation costs for the three months ended March 31, 2017 and 2016 were $5 million and $173 million, respectively. These costs were primarily attributable to significant legal proceedings and governmental investigations.

#### Gains on Sales, Consolidation and Deconsolidation of Facilities

During the three months ended March 31, 2017, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $15 million, primarily comprised of $6 million of gains related to the consolidation and deconsolidation of certain businesses of our USPI joint venture due to ownership changes and $9 million from the sale of our health plans in Michigan.

During the three months ended March 31, 2016, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $147 million, primarily comprised of a $113 million gain from the sale of our Atlanta-area facilities and $29 million of gains related to the consolidation and deconsolidation of certain businesses of our USPI joint venture due to ownership changes.

#### Interest Expense

Interest expense for the three months ended March 31, 2017 was $258 million compared to $243 million for the same period in 2016.

#### Income Tax Expense

During the three months ended March 31, 2017, we recorded an income tax benefit of $33 million in continuing operations on pre-tax income of $4 million, compared to income tax expense of $67 million on pre-tax income of $105 million during the three months ended March 31, 2016. Our provision for income taxes during interim reporting periods is calculated by applying an estimate of the annual effective tax rate for the full year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. In calculating “ordinary” income, non-taxable income or loss attributable to non-controlling interests has been deducted from pre-tax income or loss in the determination of the annualized effective tax rate used to calculate income taxes for the quarter. The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown below:

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Tax expense at statutory federal rate of 35% | $1 | $37 |
| State income taxes, net of federal income tax benefit | (7) | 13 |
| Tax benefit attributable to noncontrolling interests | (26) | (21) |
| Nondeductible goodwill | — | 29 |
| Nontaxable gains | — | (17) |
| Nondeductible litigation | — | 26 |
| Change in tax contingency reserves, including interest | (2) | (3) |
| Stock-based compensation | 8 | — |
| Other items | (7) | 3 |
|  | **$(33)** | **$67** |

#### Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $89 million for the three months ended March 31, 2017 compared to $93 million for the three months ended March 31, 2016. Net income attributable to noncontrolling interests for the three months ended March 31, 2017 was comprised of $9 million related to our Hospital Operations and other segment, $66 million related to our Ambulatory Care segment and $14 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $13 million was related to the minority interests in our USPI joint venture.

### ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non-GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, from time to time we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non-GAAP measure defined by the Company as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss (income) attributable to noncontrolling interests, (3) income (loss) from discontinued operations, (4) income tax benefit (expense), (5) other non-operating income (expense), net, (6) gain (loss) from early extinguishment of debt, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, and (12) income (loss) from divested operations and closed businesses (i.e., our health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

The Company believes the foregoing non-GAAP measure is useful to investors and analysts because it presents additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize this non-GAAP measure, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which utilize similar non-GAAP measures in their presentations. The Human Resources Committee of the Company’s Board of Directors also uses certain non-GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non-GAAP Adjusted EBITDA measure the Company utilizes may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

The table below shows the reconciliation of Adjusted EBITDA to net income available (loss attributable) to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the three months ended March 31, 2017 and 2016:

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| **Net loss attributable to Tenet Healthcare Corporation common shareholders** | **$(53)** | **$(59)** |
| Less: Net income attributable to noncontrolling interests | (89) | (93) |
| Net loss from discontinued operations, net of tax | (1) | (4) |
| Net income from continuing operations | 37 | 38 |
| Income tax expense | 33 | (67) |
| Other non-operating income (expense), net | (5) | (6) |
| Interest expense | (258) | (243) |
| Operating income | 267 | 354 |
| Litigation and investigation costs | (5) | (173) |
| Gains on sales, consolidation and deconsolidation of facilities | 15 | 147 |
| Impairment and restructuring charges, and acquisition-related costs | (33) | (28) |
| Depreciation and amortization | (221) | (212) |
| Income (loss) from divested and closed businesses | (16) | 3 |
| **Adjusted EBITDA** | $527 | $617 |
| **Net operating revenues** | **$4,813** | **$5,044** |
| **Less net operating revenues from health plans** | **65** | **127** |
| **Adjusted net operating revenues** | **$4,748** | **$4,917** |
| **Net loss from continuing operations as a % of net operating revenues** | **(1.1)%** | **(1.1)%** |
| **Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)** | **11.1%** | **12.5%** |

### LIQUIDITY AND CAPITAL RESOURCES

### CASH REQUIREMENTS

There have been no material changes to our obligations to make future cash payments under contracts and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the renegotiation of the Put/Call Agreement, as discussed in Note 18 to our accompanying Condensed Consolidated Financial Statements. Under the terms of the amended agreement, we will pay Welsh Carson approximately $711 million to buy 23.7% of our USPI joint venture in the three months ending June 30, 2017.

As part of our long-term objective to manage our capital structure, we may from time to time seek to retire, purchase, redeem or refinance some of our outstanding debt or equity securities subject to prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. These actions are part of our strategy to manage our leverage and capital structure over time, which is dependent on our total amount of debt, our cash and our operating results.

At March 31, 2017, using the last 12 months of Adjusted EBITDA, our ratio of total long-term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 6.1x. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our Credit Agreement as a source of liquidity and acquisitions that involve the assumption of long-term debt. We intend to manage this ratio by following our business plan, managing our cost structure, possible asset divestitures and through other changes in our capital structure, including, if appropriate, the issuance of equity or convertible securities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements (including those required to achieve compliance with the health information technology requirements under the American Recovery and Reinvestment Act of 2009), introduction of new medical technologies, design and construction of new buildings, and various other capital improvements, as well as commitments to make capital expenditures in connection with the acquisitions of businesses. Capital expenditures were $198 million and $208 million in the three months ended March 31, 2017 and 2016, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 2017 will total approximately $700 million to $750 million, including $179 million that was accrued as a liability at December 31, 2016.

Interest payments, net of capitalized interest, were $130 million and $132 million in the three months ended March 31, 2017 and 2016, respectively.

Income tax payments, net of tax refunds, were approximately $1 million and $6 million in the three months ended March 31, 2017 and 2016, respectively.

### SOURCES AND USES OF CASH

Our liquidity for the three months ended March 31, 2017 was primarily derived from net cash provided by operating activities, cash on hand and borrowings under our revolving credit facility. We had approximately $572 million of cash and cash equivalents on hand at March 31, 2017 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was $998 million based on our borrowing base calculation at March 31, 2017.

Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections and levels of bad debt due to shifts in payer mix and other factors.

Net cash provided by operating activities was $186 million in the three months ended March 31, 2017 compared to $147 million in the three months ended March 31, 2016. Key factors contributing to the change between the 2017 and 2016 periods include the following:

- A $45 million decrease in payments on reserves for restructuring charges, acquisition-related costs, and litigation costs and settlements; and
- A $6 million decrease in cash used in discontinued operations.

We continue to seek further initiatives to increase the efficiency of our balance sheet by generating incremental cash, including by means of the sale of underutilized or inefficient assets.

Net cash used in investing activities was $189 million for the three months ended March 31, 2017 compared to net cash provided by investing activities of $320 million for the three months ended March 31, 2016. The primary reason for the decrease was due to proceeds from sales of facilities and other assets of $20 million in the 2017 period compared to $573 million in the 2016 period when we completed the sale of our Georgia facilities. Capital expenditures were $198 million and $208 million in the three months ended March 31, 2017 and 2016, respectively.

Net cash used in financing activities was $141 million and $95 million for the three months ended March 31, 2017 and 2016, respectively. The 2017 amount included our purchase of the land and improvements associated with our Palm Beach Gardens Medical Center, which we previously leased under a capital lease, for approximately $44 million.

We record our investments that are available-for-sale at fair market value. As shown in Note 14 to our Condensed Consolidated Financial Statements, the majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.

### DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

*Credit Agreement.* We have a senior secured revolving credit facility (as amended, “Credit Agreement”), which provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. Obligations under the Credit Agreement, which has a scheduled maturity date of December 4, 2020, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first priority lien on the accounts receivable owned by us and the subsidiary guarantors. At March 31, 2017, we were in compliance with all covenants and conditions in our Credit Agreement. At March 31, 2017, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $2 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $998 million was available for borrowing under the Credit Agreement at March 31, 2017.

*Letter of Credit Facility.* We have a letter of credit facility (as amended, “LC Facility”) that provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). Obligations under the LC Facility are guaranteed by and secured by a first priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. On September 15, 2016, we entered into an amendment to our existing letter of credit facility agreement in order to, among other things, (i) extend the scheduled maturity date of the LC Facility to March 7, 2021, and reduce certain margins and fees payable under the LC Facility. At March 31, 2017, we were in compliance with all covenants and conditions in our LC Facility. At March 31, 2017, we had approximately $108 million of standby letters of credit outstanding under the LC Facility.

For information regarding our long-term debt and capital lease obligations, see Note 5 to our Condensed Consolidated Financial Statements.

### LIQUIDITY

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day-to-day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest and income tax payments. Cash flows from operating activities in the first quarter of the calendar year are usually lower than in subsequent quarters of the year, primarily due to the timing of certain working capital requirements during the first quarter, including our annual 401(k) matching contributions and annual incentive compensation payments. These fluctuations result in material intra-quarter net operating and investing uses of cash that may cause us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, availability under our Credit Agreement, anticipated future cash provided by operating activities, and our investments in marketable securities of our captive insurance companies classified as noncurrent investments on our balance sheet should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to joint venture partners, including those related to put and call arrangements, and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate cash from operations, as well as by the various risks and uncertainties discussed in this and other sections of this report, including any costs associated with legal proceedings and government investigations described in Note 10 to our Condensed Consolidated Financial Statements.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our period-end balance sheets. In addition, we do not have significant exposure to floating interest rates given that substantially all of our current long-term indebtedness has fixed rates of interest.

### OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $136 million of standby letters of credit outstanding and guarantees at March 31, 2017.

### CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.

Our critical accounting estimates have not changed from the description provided in our Annual Report.

## Market risk

As filed, 1,988 characters.

The table below presents information about certain of our market-sensitive financial instruments at March 31, 2017. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the reporting date. The effects of unamortized premiums, discounts and issue costs are excluded from the table.

*(Dollars in Millions)*

|  | Maturity Date, Years Ending December 31, 2017 | 2018 | 2019 | 2020 | 2021 | Thereafter | Total | Fair Value |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Fixed rate long-term debt | $129 | $1,160 | $1,696 | $3,419 | $1,955 | $6,184 | $14,543 | $14,335 |
| Average effective interest rates | 5.0% | 6.5% | 5.5% | 6.7% | 4.7% | 8.0% | 6.8% |  |
| Variable rate long-term debt | $— | $— | $— | $900 | $— | $— | $900 | $903 |
| Average effective interest rates | —% | —% | —% | 4.6% | —% | —% | 4.6% |  |

At March 31, 2017, the potential reduction of annual pre-tax earnings due to a one percentage point (100 basis point) increase in variable interest rates on long-term debt would be approximately $9 million.

At March 31, 2017, we had long-term, market-sensitive investments held by our captive insurance subsidiaries. Our market risk associated with our investments in debt securities classified as non-current assets is substantially mitigated by the long-term nature and type of the investments in the portfolio.

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities.

We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

## Controls and procedures

As filed, 1,060 characters.

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2016.

Filed May 1, 2017.
Source: SEC EDGAR, the filing index for accession 0001558370-17-003181. Last ingested by Listed: Nov 15, 2026, 02:42 ET. No prices; not investment advice.
